Results
|
|
1.
|
A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study. MedStar authors:
Year: 2015
Citation: - Journal of Clinical Endocrinology & Metabolism. 100(5):1855-62, 2015 May.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
All authors: - Adam KP, Banerji M, Bray GA, Buchanan TA, Clement SC, Cobb JE, DeFronzo RA, Ferrannini E, Gall W, George T, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|
|
|
2.
|
Implementation of Basal-Bolus Therapy in Type 2 Diabetes: A Randomized Controlled Trial Comparing Bolus Insulin Delivery Using an Insulin Patch with an Insulin Pen. MedStar authors:
Year: 2019
Citation: - Diabetes Technology & Therapeutics. 21(5):273-285, 2019 May.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bailey TS, Bergenstal RM, Brazg RL, Calibra Study Group, Dreon DM, Frias JP, Johnson ML, Klonoff DC, Kruger DF, Levy BL, Naik RG, Peyrot M, Ramtoola S, Rosenstock J, Serusclat P, Shearer DM, Weinstock RS, Zraick V
|
|
|
3.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
4.
|
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
Year: 2016
Citation: - Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
|
|
|
5.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
6.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
7.
|
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(11):2108-2116, 2019 11.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
|
|
|
8.
|
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. MedStar authors:
Year: 2013
Citation: - Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
|
|
|
9.
|
Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. [] MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(8):2317-25, 2014 Aug.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Ahren B, Chow FC, Fonseca VA, Gross JL, Harmony 6 Study Group, Johnson SL, Leiter LA, Miller D, Ratner RE, Rosenstock J, Stewart MW, Yang F
|
|
|
10.
|
Redesigning ambulatory care management for uncontrolled type 2 diabetes: a prospective cohort study of the impact of a Boot Camp model on outcomes. MedStar authors:
- Baker, Kelley M
- Evans, Stephen R
- Fernandez, Stephen J
- Huang, Chun-Chi
- Magee, Michelle
- Mete, Mihriye
- Montero, Alex R
- Nassar, Carine M
- Sack, Paul A
- Smith, Kelly
- Youssef, Gretchen A
Year: 2019
Citation: - BMJ Open Diabetes Research & Care. 7(1):e000731, 2019.
Institution:
- MedStar Health Research Institute
- MedStar Heart & Vascular Institute
- MedStar Institute for Quality and Safety
- MedStar Union Memorial Hospital
- MedStar Washington Hospital Center
Department:
- Medicine/Endocrinology
- MedStar Diabetes Institute
- MedStar Health, Columbia
Medline publication type:
All authors: - Baker KM, Evans SR, Fernandez SJ, Huang CC, Magee MF, Mete M, Montero AR, Nassar CM, Sack PA, Smith K, Youssef GA
|
